13P Durvalumab + chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L) osimertinib: An ORCHARD study interim analysis
Year: 2022
Type: article
Source: Annals of Oncology
Institutions: Yonsei Cancer Hospital, Samsung Medical Center, Sungkyunkwan University, Seattle Cancer Care Alliance, University of Washington, Universidade da Coruña, University of California, Los Angeles, Asan Medical Center, University of Ulsan, Seoul National University Bundang Hospital, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Spanish National Cancer Research Centre, Hospital Universitario 12 De Octubre, City Of Hope National Medical Center, Wakayama Medical University, Jikei University School of Medicine, National Cancer Centre Japan, National Cancer Center Hospital, Memorial Sloan Kettering Cancer Center, AstraZeneca (United Kingdom), AstraZeneca (United States), Kyushu University, Research Institute for Diseases of the Chest, Kyushu University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4226169283